The following is a summary of “Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy,” published in the January 2025 ...

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...

Background Multiple system atrophy (MSA ... Quantitative brain imaging using 3T MRI was performed before and after treatment. Results Nine subjects were enrolled, and seven (2 women and 5 men, ...

Local estrogen therapy is the treatment of choice for women with vulvovaginal atrophy who lack other postmenopausal symptoms. Systemic estrogen therapy is indicated for vulvovaginal atrophy only ...

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

WAND Investigates as men and women who served in classified missions for the Air Force and the Department of Defense are being denied health and other benefits because their records ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Hopes for millions of people with Alzheimer's could be on the horizon after a new drug that slows down the progression of the disease is being considered ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

A new pill that ‘slows down Alzheimer's ' is being considered for use in the NHS. Developed by a small British firm in ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...